Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study
- PMID: 28332511
- DOI: 10.1038/jhh.2017.1
Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study
Abstract
We performed a nested case-control study in a cohort of antihypertensive drug users to assess the association between discontinuation of different antihypertensive agents and the risk of acute myocardial infarction (AMI). Cases and controls were drawn from the Utrecht Cardiovascular Pharmacogenetics database. Patients who were hospitalised for their first AMI were considered cases and controls were not hospitalised for AMI. Antihypertensive users were defined as current users if the index date (date of AMI) fell within the prescribed duration or as discontinuers if this date fell outside the prescribed duration. According to the recency of discontinuation, discontinuers were divided into the following: recent discontinuers (⩽90 days), intermediate-term discontinuers (91-180 days) and long-term discontinuers (>180 days). We found that the risk of AMI was significantly increased in discontinuers, regardless of time since discontinuation, of beta-blockers (adjusted odds ratio (OR) 1.54; 95% confidence interval (CI; 1.25-1.91), P-value<0.0005), calcium channel blockers (CCBs; adjusted OR 2.25; 95% CI (1.53-3.30), P-value<0.0005) and diuretics (adjusted OR 1.76; 95% CI (1.24-2.48), P-value=0.002) compared to current users of these drugs. Moreover, the risk of AMI was significantly increased in long-term discontinuers (beta-blockers, CCBs, angiotensin-converting enzyme inhibitors and diuretics) and intermediate-term discontinuers (beta-blockers and CCBs) versus current users of these drugs. There was no difference in AMI risk between recent discontinuers of antihypertensive drugs versus current users of these drugs. In conclusion, discontinuation of antihypertensive drugs increases the risk of AMI after >90 days of discontinuation. This further underlines the importance of persistence to antihypertensive drug therapy to reduce the risk of AMI in patients with hypertension.
Similar articles
-
The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke.Curr Med Res Opin. 2008 Jan;24(1):121-7. doi: 10.1185/030079908x253843. Curr Med Res Opin. 2008. PMID: 18031596
-
Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.J Hypertens. 2005 Nov;23(11):2093-100. doi: 10.1097/01.hjh.0000186832.41125.8a. J Hypertens. 2005. PMID: 16208153
-
Antihypertensive drug prescribing and persistence among new elderly users: implications for persistence improvement interventions.Can J Cardiol. 2014 Jun;30(6):647-52. doi: 10.1016/j.cjca.2014.03.017. Epub 2014 Mar 18. Can J Cardiol. 2014. PMID: 24882536
-
The Role of Beta-Blockers in the Treatment of Hypertension.Adv Exp Med Biol. 2017;956:149-166. doi: 10.1007/5584_2016_36. Adv Exp Med Biol. 2017. PMID: 27957711 Review.
-
Fluid matters in choosing antihypertensive therapy: a hypothesis that the data speak volumes.J Am Board Fam Pract. 2005 Mar-Apr;18(2):113-24. doi: 10.3122/jabfm.18.2.113. J Am Board Fam Pract. 2005. PMID: 15798140 Review.
Cited by
-
COVID-19 and Acute Coronary Events - Collateral Damage. A Case Report.Arq Bras Cardiol. 2020 Jun;114(6):1072-1075. doi: 10.36660/abc.20200329. Epub 2020 Jul 3. Arq Bras Cardiol. 2020. PMID: 32638904 Free PMC article. English, Portuguese. No abstract available.
-
Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.J Am Heart Assoc. 2022 Sep 6;11(17):e026143. doi: 10.1161/JAHA.122.026143. Epub 2022 Aug 24. J Am Heart Assoc. 2022. PMID: 36000426 Free PMC article. Review.
-
Effect of patient and treatment factors on persistence with antihypertensive treatment: A population-based study.PLoS One. 2021 Jan 15;16(1):e0245610. doi: 10.1371/journal.pone.0245610. eCollection 2021. PLoS One. 2021. PMID: 33450744 Free PMC article.
-
Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.Hypertens Res. 2020 Jul;43(7):591-596. doi: 10.1038/s41440-020-0449-6. Epub 2020 May 7. Hypertens Res. 2020. PMID: 32382156 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical